Healthcare company Covidien (NYSE:COV) reported on Wednesday the market availability of an advanced ablation system technology that offers physicians predictable results regardless of the target location or tissue type, overcoming a significant roadblock to predictable ablation of soft tissue. The company added that its Emprint Ablation System with Thermosphere Technology is designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non- resectable liver tumors.
Hey, check out all the engineering jobs. Post your resume today!
